Journal September 25, 2026 4 min read

What is mucosal healing?

Mucosal healing is the restoration of the intestinal epithelial barrier and resolution of endoscopic lesions in inflammatory bowel disease. This page covers the formal definition, the biomarkers and pathways under study,

peptides-pro Editorial

Mucosal healing is the restoration of the intestinal mucosal barrier, defined endoscopically as the resolution of visible ulceration and inflammation in inflammatory bowel disease (IBD). It is recognized as the best therapeutic endpoint in ulcerative colitis (UC), but its use in routine practice is limited by the low acceptability of repeated colonoscopies [3]. Synonyms include endoscopic healing and mucosal repair. The term describes a clinical endpoint rather than a single molecular entity; it has no sequence, formula, or molecular weight.

The work centres on epithelial regeneration and barrier function, with the NAD-dependent deacetylase sirtuin-1 (SIRT1)/signal transducer and activator of transcription 3 (STAT3) pathway among the signaling axes under investigation in preclinical colitis models [1].

Research Studies

GHK-Cu and the SIRT1/STAT3 pathway in DSS-induced murine colitis

Glycyl-l-histidyl-l-lysine-copper (GHK-Cu) has known anti-inflammatory properties, but its therapeutic mechanisms in UC were undefined. A study was designed to evaluate GHK-Cu in a dextran sulfate sodium (DSS)-induced murine model of UC, with emphasis on its regulatory effects on the SIRT1/STAT3 signaling pathway. UC was induced in BALB/c mice [1]. This is animal-only evidence.

Fecal and serum biomarkers for predicting mucosal healing in UC patients

Because repeated colonoscopies are poorly accepted, fecal biomarkers are attractive alternatives. Fecal calprotectin showed very good negative predictive value to eliminate IBD diagnosis, good correlation to endoscopic activity, and good ability to predict relapse. Several teams, including the study authors, showed that fecal biomarkers such as Chitinase 3-Like 1 (CHI3L1) and matrix metalloprotease type 9 (MMP-9), and serum biomarkers neutrophil gelatinase B-complex associated lipocalin (NGAL)-MMP9 and serum CHI3L1, could be better [3]. This study is in patients with UC.

Lactobacillus probiotics and trace elements with infliximab in UC patients

An interventional observational study is evaluating the efficacy and safety of Lactobacillus probiotics or trace elements when added to infliximab in maintaining remission in UC patients, and comparing the efficacy of adding Lactobacillus probiotics versus adding trace elements to infliximab. The open-label, parallel, prospective study is conducted at the outpatient clinic of IBD and gastroenterology of the National Hepatology and Tropical Medicine Research Institute (NHTMRI), Cairo, Egypt. Recruited patients are randomly allocated to one of three groups; Group I will receive 20 billion colony forming [2]. This study is in UC patients.

Gene expression and mitochondrial function in IBD ulcer healing

A study compares non-healing colonic ulcers in patients with IBD with iatrogenic colonic ulcers (biopsy sites) in healthy control patients and patients with rheumatoid or psoriatic arthritis. Patients are biopsied at baseline and again at a follow-up visit in a "biopsy of the biopsy" approach. These biopsies are used to reveal patterns about gene expression and mitochondrial function during ulcer healing [4]. This study is in IBD patients and controls.

Four interventions for malnutrition enteropathy in children with severe acute malnutrition

The TAME study evaluates four approaches compared against standard care for malnutrition enteropathy in children with severe acute malnutrition. A high pathogen burden causes damage to the intestinal mucosa, which exacerbates nutritional impairment and leads to further susceptibility to infection and impaired epithelial regeneration. Enteropathy is characterized by multiple epithelial breaches, microbial translocation from gut lumen to systemic circulation, and systemic inflammation. The trial evaluates colostrum, N-acetyl glucosamine, teduglutide, and budesonide given for 14 days [5]. This study is in children with severe acute malnutrition.

Zinc L-carnosine and oral mucosal repair

A systematic review and meta-analysis evaluated zinc L-carnosine (ZnC), a cytoprotective compound with anti-inflammatory, antioxidant, and epithelial reparative properties, for oral mucosal injury, a frequent complication in oncologic and surgical settings [6]. This evidence concerns the oral mucosa, not the intestinal mucosa.

Comparison of mucosal healing contexts

Context	Population	Intervention or focus	Source
DSS-induced colitis	BALB/c mice	GHK-Cu; SIRT1/STAT3 pathway	[1]
UC remission maintenance	UC patients	Lactobacillus probiotics or trace elements added to infliximab	[2]
Biomarker prediction of mucosal healing	UC patients	Fecal calprotectin, CHI3L1, MMP-9; serum NGAL-MMP9, CHI3L1	[3]
Ulcer healing mechanisms	IBD patients; healthy controls; rheumatoid or psoriatic arthritis patients	Gene expression and mitochondrial function in colonic ulcers	[4]
Malnutrition enteropathy	Children with severe acute malnutrition	Colostrum, N-acetyl glucosamine, teduglutide, budesonide	[5]
Oral mucosal injury	Oncologic and surgical settings	Zinc L-carnosine	[6]

If you are reading this for personal health reasons

The materials described here are sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.